BTOG 2018 | Exciting randomized trials for mesothelioma: checkpoint inhibitor monotherapies and vinorelbine

Dean Fennell

Only one treatment for malignant mesothelioma has been approved since 2003 and rates of the disease are rising worldwide; thus, new treatments must be found. Here, Dean Fennell, PhD, FRCP, of University Hospitals of Leicester NHS Trust, Leicester, UK, discusses the late phase randomized trials that he is excited about. Prof. Dean highlights CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM; NCT03063450) which is investigating nivolumab; the PROMISE-meso study (NCT02991482) of pembrolizumab vs. standard chemotherapy; and the VIM trial (NCT02139904) of vinorelbine in the second-line setting. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.

Share this video